Cardiff Lexington Announces Second Quarter 2024 Financial Results
Cardiff Lexington (OTC PINK:CDIX) has announced its financial results for Q2 and H1 2024. Key highlights include:
- Q2 revenue of $2,330,964 with a 66% gross profit margin
- H1 revenue of $4,992,930 with a 65% gross profit margin
- Shareholders' equity increased by 698% to $5,837,412
- Cash increased by 269% to $3,196,795
- Total assets increased by 19% to $24,659,020
The company reported a loss from continuing operations of $202,345 in Q2, partly due to increased bad debt expense. However, for H1, income from continuing operations was $16,647. Cardiff Lexington is focusing on expanding its healthcare locations, having opened its 12th Nova Ortho and Spine location in Orlando, Florida.
Cardiff Lexington (OTC PINK:CDIX) ha annunciato i suoi risultati finanziari per il secondo trimestre e il primo semestre del 2024. I principali aspetti salienti includono:
- Fatturato del Q2 di $2,330,964 con un margine di profitto lordo del 66%
- Fatturato del H1 di $4,992,930 con un margine di profitto lordo del 65%
- Il capitale degli azionisti è aumentato del 698% arrivando a $5,837,412
- La liquidità è aumentata del 269% arrivando a $3,196,795
- Il totale delle attività è aumentato del 19% arrivando a $24,659,020
L'azienda ha registrato una perdita dalle operazioni continuative di $202,345 nel Q2, in parte a causa dell'aumento delle spese per crediti inesigibili. Tuttavia, per il H1, il reddito delle operazioni continuative è stato di $16,647. Cardiff Lexington sta concentrando i suoi sforzi sull'espansione delle sue sedi sanitarie, avendo aperto la sua dodicesima sede Nova Ortho and Spine a Orlando, Florida.
Cardiff Lexington (OTC PINK:CDIX) ha anunciado sus resultados financieros para el segundo trimestre y el primer semestre de 2024. Los principales aspectos destacados incluyen:
- Ingresos del Q2 de $2,330,964 con un margen de ganancia bruta del 66%
- Ingresos del H1 de $4,992,930 con un margen de ganancia bruta del 65%
- El patrimonio de los accionistas aumentó un 698% hasta $5,837,412
- El efectivo aumentó un 269% hasta $3,196,795
- Los activos totales aumentaron un 19% hasta $24,659,020
La empresa reportó una pérdida de operaciones continuas de $202,345 en el Q2, en parte debido al aumento de los gastos por deudas incobrables. Sin embargo, para el H1, el ingreso de operaciones continuas fue de $16,647. Cardiff Lexington se está enfocando en expandir sus ubicaciones de atención médica, habiendo abierto su duodécima ubicación de Nova Ortho and Spine en Orlando, Florida.
카디프 렉싱턴(OTC PINK:CDIX)이 2024년 2분기 및 상반기 재무 결과를 발표했습니다. 주요 하이라이트는 다음과 같습니다:
- 2분기 매출 $2,330,964로 총 이익률 66%
- 상반기 매출 $4,992,930로 총 이익률 65%
- 주주 지분이 698% 증가하여 $5,837,412에 도달
- 현금이 269% 증가하여 $3,196,795에 도달
- 총 자산이 19% 증가하여 $24,659,020에 도달
회사는 2분기 중 계속 운영으로부터 $202,345의 손실을 보고했으며, 이는 증가한 불량채권 비용 때문입니다. 그러나 상반기에는 계속 운영에서 $16,647의 수익을 올렸습니다. 카디프 렉싱턴은 플로리다 주 올랜도에 12번째 노바 오르토 앤 스파인 지점을 열면서 의료 시설 확대에 주력하고 있습니다.
Cardiff Lexington (OTC PINK:CDIX) a annoncé ses résultats financiers pour le deuxième trimestre et le premier semestre de 2024. Les points clés incluent :
- Chiffre d'affaires du Q2 de $2,330,964 avec une marge brute de 66%
- Chiffre d'affaires du H1 de $4,992,930 avec une marge brute de 65%
- Les capitaux propres des actionnaires ont augmenté de 698% pour atteindre $5,837,412
- La liquidité a augmenté de 269% pour atteindre $3,196,795
- Les actifs totaux ont augmenté de 19% pour atteindre $24,659,020
L'entreprise a signalé une perte provenant des opérations continues de $202,345 au Q2, en partie en raison de l'augmentation des dépenses liées aux créances douteuses. Cependant, pour le H1, le revenu des opérations continues était de $16,647. Cardiff Lexington se concentre sur l'expansion de ses sites de soins de santé, ayant ouvert son douzième site Nova Ortho and Spine à Orlando, Floride.
Cardiff Lexington (OTC PINK:CDIX) hat seine Finanzergebnisse für das zweite Quartal und das erste Halbjahr 2024 bekannt gegeben. Die wichtigsten Highlights sind:
- Umsatz im Q2 von $2,330,964 mit einer Bruttomarge von 66%
- Umsatz im H1 von $4,992,930 mit einer Bruttomarge von 65%
- Das Eigenkapital der Aktionäre stieg um 698% auf $5,837,412
- Die liquiden Mittel stiegen um 269% auf $3,196,795
- Die Gesamtaktiva stiegen um 19% auf $24,659,020
Das Unternehmen berichtete im Q2 von einem Verlust aus fortgeführten Betrieben in Höhe von $202,345, zum Teil aufgrund von erhöhten uneinbringlichen Forderungen. Für das H1 betrug das Einkommen aus fortgeführten Betrieben jedoch $16,647. Cardiff Lexington konzentriert sich darauf, seine Gesundheitsstandorte zu erweitern und hat seine zwölfte Nova Ortho and Spine-Niederlassung in Orlando, Florida, eröffnet.
- Shareholders' equity increased by 698% to $5,837,412
- Cash position increased by 269% to $3,196,795
- Total assets increased by 19% to $24,659,020
- Gross profit margins remained strong at 66% for Q2 and 65% for H1
- Expansion of healthcare network with 12th Nova Ortho and Spine location opened in Orlando
- Q2 loss from continuing operations of $202,345
- Increased bad debt expense of $902,183 in Q2 due to accepting lower patient claims settlement amounts
- Q2 Adjusted EBITDA loss of $118,428
- Revenue impact due to timing of certain larger surgeries
Significantly enhanced balance sheet positions company for long-term growth
LEXINGTON, KY. / ACCESSWIRE / August 20, 2024 / Cardiff Lexington Corporation (OTC PINK:CDIX) announced today financial results for its second quarter and six months ended June 30, 2024.
Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "Our second quarter results were highlighted by a significantly improved balance sheet with shareholders' equity increasing to
"Among the many important initiatives underway, a major focus for our business is to continue expanding our network of healthcare locations throughout Florida and the broader southeast United States. To that end, we opened our 12th Nova Ortho and Spine location in Orlando, Florida subsequent to the close of the quarter. This location is performing well, and further enhances our visibility and patient access while providing us with a key presence in a larger metropolitan market.
"While our second quarter revenue was impacted by the timing of certain larger surgeries, we are on track to drive strengthened revenue and earnings performance in the back half of the year and into 2025 driven by an expanded network of healthcare locations and a strong reputation as a provider of high-quality medical care in a high-volume market."
Second Quarter 2024 Financial Highlights
Revenue of
$2,330,964. Gross profit margin of
66% .Loss from continuing operations was
$202,345. Included in SG&A expenses in 2Q 2024 were higher expenses associated with the anticipated growth of the business as well as charges for increased bad debt expense of$902,183 as a result of accepting lower patient claims settlement amounts due to efforts to accelerate cash collection.Adjusted EBITDA was a loss of
$118,428.
Six Months 2024 Financial Highlights
Revenue of
$4,992,930. Gross profit margin of
65% .Income from continuing operations was
$16,647. Included in operating expenses for the six months ended June 30, 2024 were increased expenses associated with the anticipated growth of the business, and increased bad debt expense of$1,242,017 as referenced above.Adjusted EBITDA was
$403,154.
Balance Sheet Highlights (June 30, 2024 compared to December 31, 2023)
269% increase in cash to$3,196,795. 19% increase in total assets to$24,659,020. 698% increase in shareholders' equity to$5,837,412.
Mr. Cunningham concluded, "As one of the fastest growing sectors in U.S. healthcare, it's becoming increasingly clear that orthopedic healthcare is a very attractive long-term growth market for us. Compared to other clinical specialties, orthopedics remains highly fragmented, and over the next decade, we believe that healthcare providers will continue to experience increasing demand primarily driven by an aging patient population and a rising number of car accidents nationwide. The trajectory of this market is encouraging, and we're optimistic about our growth prospects - both organic and through acquisition - that we believe will help us to drive enhanced value for shareholders."
-----
About Cardiff Lexington Corporation:
Cardiff Lexington Corporation is a holding company focused on locating, acquiring, and building middle market, niche companies, primarily in the healthcare industry. Fundamental to the Cardiff Lexington strategy is the service-based partnership culture which emphasizes core values, teamwork, accountability, and performance.
A substantial majority of the Company's revenue is derived from Nova Ortho and Spine, LLC, which operates a group of regional primary specialty and ancillary care facilities throughout Florida that provide traumatic injury victims with a full range of diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultation services.
For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/
FORWARD-LOOKING STATEMENT: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.
Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705
or
IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 and 2023
(UNAUDITED)
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| |||||||||||
| 2024 |
|
| 2023 (Restated) |
|
| 2024 |
|
| 2023 (Restated) |
| |||||
REVENUE |
| $ | 2,330,964 |
|
| $ | 3,364,506 |
|
| $ | 4,992,930 |
|
| $ | 6,070,905 |
|
COST OF SALES |
|
| 793,010 |
|
|
| 1,081,689 |
|
|
| 1,741,164 |
|
|
| 2,037,984 |
|
GROSS PROFIT |
|
| 1,537,954 |
|
|
| 2,282,817 |
|
|
| 3,251,766 |
|
|
| 4,032,921 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
OPERATING EXPENSES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation expense |
|
| 3,366 |
|
|
| 3,365 |
|
|
| 6,731 |
|
|
| 8,000 |
|
Share based compensation |
|
| - |
|
|
| - |
|
|
| 300,225 |
|
|
| - |
|
Selling, general and administrative |
|
| 1,736,933 |
|
|
| 530,013 |
|
|
| 2,928,163 |
|
|
| 1,517,933 |
|
Total operating expenses |
|
| 1,740,299 |
|
|
| 533,378 |
|
|
| 3,235,119 |
|
|
| 1,525,933 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
(LOSS) INCOME FROM CONTINUING OPERATIONS |
|
| (202,345 | ) |
|
| 1,749,439 |
|
|
| 16,647 |
|
|
| 2,506,988 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
OTHER INCOME (EXPENSE) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income |
|
| 2,047 |
|
|
| - |
|
|
| 2,047 |
|
|
| 204 |
|
Gain on debt refinance and forgiveness |
|
| 78,834 |
|
|
| - |
|
|
| 78,834 |
|
|
| 390 |
|
Penalties and fees |
|
| (330 | ) |
|
| (15,000 | ) |
|
| (1,330 | ) |
|
| (32,000 | ) |
Interest expense |
|
| (41,347 | ) |
|
| (843,918 | ) |
|
| (417,616 | ) |
|
| (1,537,579 | ) |
Amortization of debt discounts |
|
| (11,306 | ) |
|
| (30,633 | ) |
|
| (24,821 | ) |
|
| (48,616 | ) |
Total other income (expense) |
|
| 27,898 |
|
|
| (889,551 | ) |
|
| (362,886 | ) |
|
| (1,617,601 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
NET (LOSS) INCOME BEFORE DISCONTINUED OPERATIONS |
|
| (174,447 | ) |
|
| 859,888 |
|
|
| (346,239 | ) |
|
| 889,387 |
|
LOSS FROM DISCONTINUED OPERATIONS |
|
| - |
|
|
| (43,810 | ) |
|
| (111,312 | ) |
|
| (89,300 | ) |
NET (LOSS) INCOME FOR THE PERIOD |
| $ | (174,447 | ) |
| $ | 816,078 |
|
| $ | (457,551 | ) |
| $ | 800,087 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
PREFERRED STOCK DIVIDENDS |
|
| (326,174 | ) |
| $ | (125,744 | ) |
| $ | (477,808 | ) |
|
| (454,419 | ) |
NET (LOSS) INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS |
| $ | (500,621 | ) |
| $ | 690,334 |
|
| $ | (935,359 | ) |
| $ | 345,668 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
BASIC (LOSS) INCOME PER SHARE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONTINUING OPERATIONS |
| $ | (0.04 | ) |
| $ | 55.66 |
|
| $ | (0.11 | ) |
| $ | 28.75 |
|
DISCONTINUED OPERATIONS |
| $ | 0.00 |
|
| $ | (3.53 | ) |
| $ | (0.01 | ) |
| $ | (7.43 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
DILUTED (LOSS) INCOME PER SHARE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONTINUING OPERATIONS |
| $ | (0.04 | ) |
| $ | 3.59 |
|
| $ | (0.11 | ) |
| $ | 1.45 |
|
DISCONTINUED OPERATIONS |
| $ | 0.00 |
|
| $ | (3.53 | ) |
| $ | (0.01 | ) |
| $ | (7.43 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
WEIGHTED AVERAGE SHARES OUTSTANDING - BASIC |
|
| 12,792,767 |
|
|
| 12,403 |
|
|
| 8,305,493 |
|
|
| 12,024 |
|
WEIGHTED AVERAGE SHARES OUTSTANDING - DILUTED |
|
| 12,792,767 |
|
|
| 192,477 |
|
|
| 8,305,493 |
|
|
| 237,814 |
|
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF JUNE 30, 2024 AND DECEMBER 31, 2023
(UNAUDITED)
|
|
|
| December 31, 2023 |
| |||
| June 30, 2024 |
|
| (Restated) |
| |||
ASSETS |
|
|
|
|
|
| ||
Current assets |
|
|
|
|
|
| ||
Cash |
| $ | 3,196,795 |
|
| $ | 866,943 |
|
Accounts receivable-net |
|
| 14,818,277 |
|
|
| 13,305,254 |
|
Prepaid and other current assets |
|
| 5,000 |
|
|
| 5,000 |
|
Total current assets |
|
| 18,020,072 |
|
|
| 14,177,197 |
|
|
|
|
|
|
|
|
| |
Property and equipment, net |
|
| 27,929 |
|
|
| 34,661 |
|
Land |
|
| 540,000 |
|
|
| 540,000 |
|
Goodwill |
|
| 5,666,608 |
|
|
| 5,666,608 |
|
Right of use - assets |
|
| 348,702 |
|
|
| 289,062 |
|
Due from related party |
|
| 4,979 |
|
|
| 4,979 |
|
Other assets |
|
| 50,730 |
|
|
| 33,304 |
|
Total assets |
| $ | 24,659,020 |
|
| $ | 20,745,811 |
|
|
|
|
|
|
|
|
| |
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable and accrued expense |
| $ | 1,679,731 |
|
| $ | 2,047,131 |
|
Accrued expenses - related parties |
|
| 4,353,056 |
|
|
| 4,733,057 |
|
Accrued interest |
|
| 103,345 |
|
|
| 620,963 |
|
Right of use - liabilities |
|
| 173,985 |
|
|
| 157,669 |
|
Due to director and officer |
|
| - |
|
|
| 120,997 |
|
Notes payable - current portion |
|
| 550,900 |
|
|
| 15,977 |
|
Line of credit |
|
| 6,675,746 |
|
|
| 2,120,100 |
|
Convertible notes payable, net of debt discounts of |
|
| 110,000 |
|
|
| 3,807,030 |
|
Net liabilities of discontinued operations |
|
| 237,643 |
|
|
| 237,643 |
|
Total current liabilities |
|
| 13,884,406 |
|
|
| 13,860,567 |
|
|
|
|
|
|
|
|
| |
Notes payable |
|
| 142,391 |
|
|
| 144,666 |
|
Operating lease liability - long term |
|
| 169,811 |
|
|
| 119,056 |
|
Total liabilities |
|
| 14,196,608 |
|
|
| 14,124,289 |
|
|
|
|
|
|
|
|
| |
Mezzanine equity |
|
|
|
|
|
|
|
|
Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, |
|
| 3,125,000 |
|
|
| 3,891,439 |
|
Redeemable Series R Senior Convertible Preferred Stock - 5,000 shares authorized, |
|
| - |
|
|
| 307,980 |
|
Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, |
|
| 1,500,000 |
|
|
| 1,690,685 |
|
Total Mezzanine Equity |
|
| 4,625,000 |
|
|
| 5,890,104 |
|
|
|
|
|
|
|
|
| |
Stockholders' equity |
|
|
|
|
|
|
|
|
Series B Preferred Stock - 3,000,000 shares authorized, |
|
| 3,920,716 |
|
|
| 8,557,912 |
|
Series C Preferred Stock - 500 shares authorized, |
|
| 240 |
|
|
| 492 |
|
Series E Preferred Stock - 1,000,000 shares authorized, |
|
| 301,500 |
|
|
| 623,000 |
|
Series F-1 Preferred Stock - 50,000 shares authorized, |
|
| 103,000 |
|
|
| 143,008 |
|
Series I Preferred Stock - 15,000,000 shares authorized, |
|
| 46,562,000 |
|
|
| 59,540,000 |
|
Series J Preferred Stock - 2,000,000 shares authorized, |
|
| - |
|
|
| 6,854,336 |
|
Series L Preferred Stock - 400,000 shares authorized, |
|
| 1,277,972 |
|
|
| 1,277,972 |
|
Series Y Senior Convertible Preferred Stock - 1,000,000 shares authorized, |
|
| 3,755,632 |
|
|
| - |
|
Common Stock; 300,000,000 shares authorized, |
|
| 13,626 |
|
|
| 25 |
|
Additional paid-in capital |
|
| 19,522,200 |
|
|
| (7,581,212 | ) |
Accumulated deficit |
|
| (69,619,474 | ) |
|
| (68,684,115 | ) |
Total stockholders' equity |
|
| 5,837,412 |
|
|
| 731,418 |
|
Total liabilities, mezzanine equity and stockholders' equity |
| $ | 24,659,020 |
|
| $ | 20,745,811 |
|
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023
(UNAUDITED)
The following table reconciles Net income (loss) before discontinued operations (a GAAP measure) to EBITDA (a non-GAAP measure)
|
|
|
| Unaudited |
|
|
|
|
|
|
| |||||
| For the Three Months Ended |
|
| For the Six Months Ended |
|
|
|
|
|
|
| |||||
| June 30, |
|
| June 30, |
|
|
|
|
|
|
| |||||
| 2024 |
|
| 2023 (Restated) |
|
| 2024 |
|
| 2023 (Restated) |
| |||||
EBITDA (1) |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net income (loss) before discontinued operations |
| $ | (174,447 | ) |
| $ | 859,888 |
|
| $ | (346,239 | ) |
| $ | 889,387 |
|
Add: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest |
|
| 41,347 |
|
|
| 843,918 |
|
|
| 417,616 |
|
|
| 1,537,579 |
|
Taxes |
|
| 0 |
|
|
| 0 |
|
|
| 0 |
|
|
| 0 |
|
Depreciation |
|
| 3,366 |
|
|
| 3,365 |
|
|
| 6,731 |
|
|
| 8,000 |
|
Amortization |
|
| 11,306 |
|
|
| 30,633 |
|
|
| 24,821 |
|
|
| 48,616 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
EBITDA (1) |
| $ | (118,428 | ) |
| $ | 1,737,804 |
|
| $ | 102,929 |
|
| $ | 2,483,582 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Adjusted EBITDA (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA |
| $ | (118,428 | ) |
| $ | 1,737,804 |
|
| $ | 102,929 |
|
| $ | 2,483,582 |
|
Add: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock compensation expense for shares issued |
|
| 0 |
|
|
| 0 |
|
|
| 300,225 |
|
|
| 0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Adjusted EBITDA (2) |
| $ | (118,428 | ) |
| $ | 1,737,804 |
|
| $ | 403,154 |
|
| $ | 2,483,582 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |||||||||
|
|
|
|
|
|
|
| |||||||||
Contact Information
Walter Frank
Investor Relations
cardifflexington@imsinvestorrelations.com
2039729200
SOURCE: Cardiff Lexington Corporation
View the original press release on accesswire.com
FAQ
What was Cardiff Lexington's (CDIX) revenue for Q2 2024?
How much did Cardiff Lexington's (CDIX) shareholders' equity increase in H1 2024?
What was Cardiff Lexington's (CDIX) cash position as of June 30, 2024?
How many Nova Ortho and Spine locations does Cardiff Lexington (CDIX) have as of Q2 2024?
